Saturday 17 October 2026
Export NIVF’s income statement to Excel — free account
NewGenIvf Group Limited
NIVF Healthcare Medical Care Facilities
NewGenIvf Group Limited’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 13.0% from fiscal 2024. Dividend growth for five consecutive years; insiders bought in the last twelve months.
0.28
0.03
+12.00%
Follow NIVF
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '17 | |
|---|---|---|---|---|---|---|
Altman Z-Score |
(0.24) | — | — | 2,714,739.26 | — | — |
Altman Z″-Score (non-manufacturers) |
3.74 | (2.56) | 4.43 | (0.06) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Beneish M-Score |
7.81 | 7.78 | (0.31) | — | — | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(0.17) | 0.00 | 0.00 | 0.00 | — | — |
EV/FCF |
(0.17) | 0.00 | 0.00 | 0.00 | — | — |
Quick Ratio |
0.73 | 0.62 | 0.37 | 0.89 | — | — |
Current Ratio |
3.12 | 1.17 | 2.19 | 0.94 | — | — |
Net Debt/EBITDA |
(0.32) | (1.69) | (0.74) | (0.04) | — | — |
Debt/Assets |
12.52% | 65.09% | 0.00% | 0.22% | 0.00% | 0.00% |
Debt/Equity |
0.16 | (1.57) | 0.00 | 0.06 | — | — |
Asset Turnover |
0.26 | 1.35 | 1.39 | 4.09 | 0.00 | — |
Operating CF/Net income |
(1.11) | 15.75 | (13.56) | 3.73 | — | — |
Capex/Depreciation |
(0.56) | (1.00) | (2.24) | (0.94) | — | — |
Interest Coverage |
(17.40) | (1.49) | 0.91 | 5.12 | — | — |
| 80.63% | (59.49%) | 7.78% | 0.00% | — | — | |
| 54.43% | (13.01%) | 3.52% | 31.58% | 0.00% | — | |
ROIC |
(22.86%) | (186.26%) | 0.83% | 313.44% | — | — |
Return on Tangible Assets |
145.15% | (72.32%) | 8.69% | (1,333.43%) | — | — |
Average Days of Receivables |
74.18 | 83.37 | 25.85 | 138.40 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
247.17% | 54.98% | 31.92% | 19.03% | — | — |
Intangible Assets out of Total Assets |
0.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | — | — |
Revenue per Share |
926.75 | 0.00 | 0.00 | 10.32 | — | — |
Operating CF per Share |
(2,142.37) | 0.00 | 0.00 | 2.97 | — | — |
Capex per Share |
(26.47) | 0.00 | 0.00 | (0.16) | — | — |
Free Cash Flow per Share |
(2,168.84) | 0.00 | 0.00 | 2.81 | — | — |
Cash per Share |
148.75 | 0.00 | 0.00 | 0.05 | — | — |
Shareholders Equity per Share |
5,095.43 | 0.00 | 0.00 | 0.17 | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
5,095.43 | 0.00 | 0.00 | 0.17 | — | — |
Free Cash Flow |
(11.06) | (8.32) | (1.84) | 1.62 | — | — |
Working Capital |
5.02 | 0.45 | 1.34 | (0.16) | — | — |
Capital Expenditures |
(0.13) | (0.05) | (0.07) | (0.09) | — | — |
Net Current Asset Value |
0.65 | (1.89) | 1.22 | (0.41) | — | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.03 | 0.01 | 0.01 | 0.02 | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
0.14 | 0.19 | 0.19 | 0.82 | — | — |
Cash ROIC |
(35.86%) | (637.42%) | (55.64%) | 1,200.00% | — | — |
Accounts Receivable Turnover |
4.29 | 6.77 | 3.92 | 0.00 | — | — |
Accounts Payable Turnover |
3.63 | 4.90 | 24.91 | 0.00 | — | — |
Inventory Turnover |
18.12 | 34.83 | 39.89 | 0.00 | — | — |
Average Days of Payables |
75.44 | 131.47 | 18.24 | 8.67 | — | — |
Days of Inventory on Hand |
32.47 | 8.18 | 13.35 | 3.88 | — | — |
Average Receivables |
1.10 | 0.80 | 1.31 | — | — | — |
Average Payables |
1.04 | 0.74 | 0.14 | — | — | — |
Average Inventory |
0.21 | 0.10 | 0.09 | — | — | — |
Average Assets |
18.15 | 4.03 | 3.70 | 1.45 | 0.00 | — |
Average Common Equity |
12.25 | 0.88 | 1.67 | — | — | — |
Columns are period end dates · fundamentals updated 9 Oct 2026